Orthopedics Medical News about osteoporosis; intravenous zoledronic acid

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
Core Evidence, 08/05/09

Lewiecki EM – Zoledronic acid 5 mg administered as an annual 15–min intravenous infusion has been shown to reduce the risk of vertebral fractures, hip fractures, and other fractures in a three–year randomized, double–blind, placebo–controlled trial in women with postmenopausal osteoporosis. In a randomized, double–blind, placebo–controlled trial in women and men with a recent surgical repair of low–trauma hip fracture, it reduced the risk of new clinical fractures and improved survival. In both studies, zoledronic acid was associated with a good safety profile and was generally well tolerated. Zoledronic acid has the potential to improve clinical outcomes by reducing the risk of fracture in patients with osteoporosis.

<< Previous
Prolonged treatment with the Pavlik harness in infants with...

Next >>
Fusionless Instrumentation Systems for Congenital Scoliosis:...